The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 26, 2023

Filed:

Sep. 08, 2020
Applicant:

University of Notre Dame Du Lac, South Bend, IN (US);

Inventor:

Steven Buechler, Granger, IN (US);

Assignee:

University of Notre Dame du Lac, South Bend, IN (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C12Q 1/6886 (2018.01); G16H 20/40 (2018.01); G16H 70/60 (2018.01); G16H 10/40 (2018.01); G16H 50/20 (2018.01); G16B 25/10 (2019.01); G16B 40/00 (2019.01); G16B 30/00 (2019.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); G16B 25/10 (2019.02); G16B 30/00 (2019.02); G16B 40/00 (2019.02); G16H 10/40 (2018.01); G16H 20/40 (2018.01); G16H 50/20 (2018.01); G16H 70/60 (2018.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01);
Abstract

Disclosed are genetic methods and tools for colon cancer disease classification in disease subtypes, CMS1, CMS2, CMS3, CMS4, as well as improved methods for rapid, more accurate, and more reliably reproducible disease subtype determination. Tailored treatment protocols are also provided, employing the predicted CMS of the subject sample. Genetic sequence binding targets for some or all of these gene panels may be affixed to a solid substrate, and included as part of a screening tool and/or diagnostic kit. The expression levels of the genes may be assessed to provide a genetic signature for a subtype or lack of subtype (CMS1, CMS2, CMS3, CMS4, combination subtype). The methods employ a scoring system, wherein a score is derived from the genetic expression profile/signature of the panel of selected genes, and a qualifying continuous score for each CMS subtype is determined against a predictive threshold for each colon cancer subtype.


Find Patent Forward Citations

Loading…